Seaport Therapeutics, Inc.

Overview

Compare with another stock.

• TickerSPTX on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersBoston, Massachusetts¹
• Incorporated inDE³
• Business address6 Tide Street, Suite 400, Boston, Ma 02110³
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Seaport Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Seaport Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief financial officerLauren White Apr 30, 2026 to now⁴

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorDaphne Zohar named Oct 31, 2024¹⁶
• Executive OfficerEric Green named Oct 31, 2024¹⁶
• Executive OfficerMichael Chen named Oct 31, 2024¹⁶
• DirectorBharatt I. Chowrira named Oct 31, 2024¹⁶
• DirectorEric Elenko named Oct 31, 2024¹⁶
• DirectorRobert I. Nelsen named Oct 31, 2024¹⁶
• DirectorSteven Paul named Oct 31, 2024¹⁶

Timeline

1. Aug 3, 20268-K Results of operations¹⁷
2. Jun 8, 20268-K Results of operations¹⁸
3. May 4, 20268-K Bylaws or fiscal year changed¹⁹

Calendar

Coming up

1. Nov 2, 2026Reports results for the quarter ending Sep/2026²⁰

When it reported results

1. Aug 3, 2026Reported quarterly or annual results¹⁷
2. Jun 8, 2026Reported quarterly or annual results¹⁸

Drug trials and FDA: coming up

1. Mar 2027Phase 2 trial readout expected Phase 2 trial of SPT-300 in Major Depressive Disorder (MDD): primary completion expected Mar 2027 (ClinicalTrials.gov NCT07065240).²¹
2. May 2027Phase 2 trial readout expected Phase 2 trial of SPT-300 in Major Depressive Disorder (MDD): primary completion expected May 2027 (ClinicalTrials.gov NCT07161700).²²

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

55 filings to the SEC since October 2021: 2 quarterly reports, 3 major events, 32 insider forms, 6 large holders, 1 private raises, 11 other. The latest 20:

1. Aug 14, 2026SCHEDULE 13G EDGAR
2. Aug 5, 2026SCHEDULE 13G EDGAR
3. Aug 5, 2026SCHEDULE 13G EDGAR
4. Aug 3, 202610-Q EDGAR
5. Aug 3, 20268-K EDGAR
6. Jun 24, 20264 EDGAR
7. Jun 8, 202610-Q EDGAR
8. Jun 8, 20268-K EDGAR
9. May 11, 2026SCHEDULE 13D EDGAR
10. May 11, 2026SCHEDULE 13G EDGAR
11. May 6, 20264 EDGAR
12. May 6, 2026SCHEDULE 13D EDGAR
13. May 6, 20263 OWNERSHIP DOCUMENT EDGAR
14. May 6, 20263 OWNERSHIP DOCUMENT EDGAR
15. May 4, 20264 EDGAR
16. May 4, 20264 EDGAR
17. May 4, 20264 EDGAR
18. May 4, 20264 EDGAR
19. May 4, 20264 EDGAR
20. May 4, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• PureTech LYT, Inc.SCHEDULE 13G, 1 filing Aug 14, 2026²³
• Daphne ZoharSCHEDULE 13G, 1 filing Aug 5, 2026²⁴
• Steven M. PaulSCHEDULE 13G, 1 filing Aug 5, 2026²⁵
• GENERAL ATLANTIC, L.P.SCHEDULE 13D, 1 filing May 11, 2026²⁶
• Goldman SachsSCHEDULE 13G, 1 filing May 11, 2026²⁷
• ARCH Venture Fund XII, L.P.SCHEDULE 13D, 1 filing May 6, 2026²⁸

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Oct 18, 2024Raised $225.9 million in a private offering of equity¹⁶ Form D: $226 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 54. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Seaport Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARSeaport Therapeutics, Inc.¹
• CIK0002042347
• Employer ID (EIN)99-2235719¹
• Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address6 Tide Street, Suite 400, Boston, MA 02110¹
• Phone617-807-4062¹
• Shares outstanding53,530,550 as of Jul 27, 2026²⁹
• On EDGAR sinceOct 31, 2024¹
• Filings55 in all: 3 (17), 4 (15), SCHEDULE 13G (4), 8-K (3), 10-Q (2), DRS/A (2), SCHEDULE 13D (2), 424B4 (1)¹
  All 17 form types

  8-A12B (1), CERT (1), D (1), DRS (1), EFFECT (1), S-1 (1), S-1/A (1), S-1MEF (1), S-8 (1)

• Latest filingsQuarterly report (10-Q) Aug 3, 2026
  Latest 8-K (8-K) Aug 3, 2026